Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab trial in chronic plaque psoriasis after TNF-alpha antagonist failure
2013-001855-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of secukinumab in psoriasis and plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: PASI 75 response at Week 16. Started Jul 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2013-001855-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001855-11.